Active Ingredient History
Tabalumab is an anti-B-cell activating factor (BAFF) human monoclonal antibody designed for the treatment of autoimmune diseases and B cell malignancies. Tabalumab was developed by Eli Lilly and Company. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Arthritis, Rheumatoid (Phase 3)
Autoimmune Diseases (Phase 3)
Connective Tissue Diseases (Phase 3)
Kidney Failure, Chronic (Phase 2)
Lupus Erythematosus, Systemic (Phase 3)
Multiple Myeloma (Phase 2)
Multiple Sclerosis, Relapsing-Remitting (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue